Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years

Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents

Inclusion Criteria:

Inclusion Criteria

• Aged 8 to 14 years at the time of enrollment.
• Healthy male or female subjects
• Negative urine pregnancy test for female subjects

Exclusion Criteria:

Exclusion Criteria

• Prior vaccination with a meningococcal B vaccine
• Prior meningococcal disease